Neosynephrin-Pos 10 % (Phenylephrine Hydrochloride)

Phenylephrine hydrochloride selectively stimulates alpha‑1 adrenergic receptors on the dilator pupillae muscle, causing smooth‑muscle contraction that widens the pupil (mydriasis) and induces cycloplegia by relaxing the ciliary muscle, facilitating clear visualization of intra‑ocular structures.

The specific dose and frequency are determined by the prescribing eye‑care professional based on the intended examination or procedure. The prescriber will decide the number of drops and timing appropriate for each patient.

Safety data for phenylephrine hydrochloride in pregnancy and lactation are limited. It is classified as pregnancy category unknown, so it should only be used if the potential benefit justifies the potential risk to the fetus, and caution is advised for breastfeeding mothers.

Enquiries are submitted through the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Phenylephrine is a selective alpha‑1 agonist, providing rapid pupil dilation with minimal cycloplegia compared with agents like tropicamide, which act on muscarinic receptors. Phenylephrine’s effect is often shorter‑lasting and may be preferred when a brief, strong mydriatic response is needed.

Store the ophthalmic solution at room temperature, below 25 °C, in its original container. Protect it from direct light, moisture and extreme temperatures to maintain stability and potency.

The solution is applied topically to the conjunctival sac of the eye. Typically, one to two drops are instilled in the affected eye(s) as directed by the eye‑care professional, with the patient instructed to keep the eye closed briefly to enhance absorption.

Serious risks include severe hypertension, hypertensive crisis, acute angle‑closure glaucoma, cardiac arrhythmias, systemic vasoconstriction, and rare allergic reactions such as anaphylaxis. Patients should be monitored for these events, especially if they have cardiovascular disease or narrow‑angle glaucoma.

Patients with known narrow‑angle or acute angle‑closure glaucoma, uncontrolled hypertension, severe cardiovascular disease, or hypersensitivity to phenylephrine or any formulation component should avoid using this product.